Is Immuneering Corporation (IMRX) a Buy, Sell, or Hold?
NASDAQ : IMRX
Immuneering Corporation
$4.78 USD
-$0.38 (-7.36%)
- Volume
- 1.28M
- Average Volume
- 1.54M
- Market Capitalization
- $173.53M
- P/E Ratio
- -4.09
- Dividend Yield
- 0.00%
- Price Target
- $14.50
- Year High
- $10.08
- Year Low
- $2.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $32.45
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Benjamin J. Zeskind |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | IMRX |
| CUSIP | 45254E107 |
| CIK | 0001790340 |
| Web | https://immuneering.com |
| Phone | 617 500 8080 |
| Currency | USD |
| Employees | 37 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.02 |
| Payout Ratio | 0.00 |
| Current Ratio | 32.45 |
| Quick Ratio | 32.45 |
| Cash Ratio | 0.01 |
Sales & Book Value
| Annual Sales | -$ |
| Price / Sales | 0.00 |
| Cash Flow | -1.13 |
| Price / Cash Flow | -3.48 |
| Price / Book | 0.00 |
Price Target and Rating
| Average Stock Price Forecast | $14.50 |
| High Stock Price Forecast | $17.00 |
| Low Stock Price Forecast | $12.00 |
| Forecast Upside/Downside | -67.03% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 11 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.27 |
| Trailing P/E Ratio | -4.09 |
| PEG Ratio | -0.07 |
| P/E Growth | -0.07 |
| Net Income | -$56.02M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -0.11% |
| Return on Assets | -0.03% |
Financials Score
| AltmanZ Score | -1.03 |
| Piotroski Score | 2.00 |
| Working Capital | 156.43B |
| Total Assets | 214.81B |
| Ebit | -59.64M |
| Market Cap | 189.14M |
| Total Liabilities | 8.29B |
Poll Results
About Immuneering Corporation (NASDAQ:IMRX) Stock
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporat ... ion is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
2026-07-15 13:01:04
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Immuneering Appoints Andrew Gengos as Chief Financial Officer
2026-06-15 07:30:00
- Former CFO of Terns Pharmaceuticals to join Immuneering - - Seasoned public company CFO strengthens team with over 25 years of leadership in biotech – NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for $6.7 billion.
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
2026-06-12 10:51:23
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
2026-06-11 07:30:00
Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard GnP alone Topline data readout, including primary endpoint of overall survival, anticipated in mid-2028 NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that the first patient has been dosed in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer patients. Atebimetinib is a novel MEK inhibitor with a pulsatile mechanism designed to target RAS, RAF, and other MAPK pathway-driven cancers with greater durability and tolerability than traditional chronic inhibitors.
2026-06-01 14:14:06
Immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer Transcript
2026-06-01 07:30:00
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Can
2026-05-21 17:00:00
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-15 07:35:00
- New survival data from Phase 2a clinical trial evaluating atebimetinibmGnP in first-line metastatic pancreatic cancer to be presented in an oral session at 2026 ASCO Annual Meeting - - Pivotal Phase 3 MAPKeeper 301 trial of atebimetinibmGnP in first-line metastatic pancreatic cancer now recruiting (NCT07562152),with first patient dosing on track for mid-2026 - - 27 months progression-free survival to date in a third-line pancreatic cancer patient receiving atebimetinib monotherapy, with an ongoing 85% reduction in tumor burden - - Ended Q1 2026 with $198.
Frequently Asked Questions
-
What is the current Immuneering Corporation (IMRX) stock price?
-
Immuneering Corporation(NASDAQ:IMRX) stock price is $4.78 in the last trading session. During the trading session, IMRX stock reached the peak price of $10.08 while $2.9 was the lowest point it dropped to. The percentage change in IMRX stock occurred in the recent session was --7.36% while the dollar amount for the price change in IMRX stock was -$0.38.
-
IMRX's industry and sector of operation?
-
The NASDAQ listed IMRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of IMRX?
-
Brett Hall | Chief Scientific Officer
Paula George | Director of Accounting & Operations and Assistant Corporation Controller
Michael D. Bookman | Chief Legal Officer & Secretary
Peter King | Head of Discovery & Vice President
Leah R. Neufeld | Chief People Officer -
How many employees does IMRX have?
-
Number of IMRX employees currently stands at 37. IMRX operates from 245 Main Street, Cambridge, MA 02142, US.
-
Link for IMRX official website?
-
Official Website of IMRX is: https://immuneering.com
-
How do I contact IMRX?
-
IMRX could be contacted at phone #617 500 8080 and can also be accessed through its website. IMRX operates from 245 Main Street, Cambridge, MA 02142, US.
-
How many shares of IMRX are traded daily?
-
The average number of IMRX shares traded daily for last 3 months was 1.54M.
-
What is the market cap of IMRX currently?
-
The market value of IMRX currently stands at $173.53M with its latest stock price at $4.78